RISK FOR FEBRILE NEUTROPENIA AMONG PATIENTS UNDERGOING CHEMOTHERAPY

Dr. Thenmozhi. P, Nishanthi. D

Abstract


Introduction: Febrile Neutropenia is a rapid decline in absolute neutrophil count is developed in response to the effects of chemotherapy in seven to fourteen days after treatment which increase the morbidity and mortality of patients receiving chemotherapy. Hence the study was conducted with aimed to assess the level of risk for febrile neutropenia among patients undergoing chemotherapy.  

Materials and Methods: Descriptive study design was employed with 100 samples who matched the inclusion criteria were selected by convenience sampling technique. Demographic variables were collected by using multiple choice questionnaires followed by MASCC (Multinational Association for Supportive Care in Cancer) FN risk index score scale were used to collect data to assess the level of risk for febrile neutropenia. The data were tabulated and analyzed by descriptive and inferential statistics. Results: The finding of the study reveals that 58% were on high risk for febrile neutropenia and 42% were on low risk for febrile neutropenia. Conclusion: special precautions to be followed prevent the infection along with administration of biological therapies to boost the immune system. Educate the health care personnel regarding febrile neutropenia risk assessment and its management.

 


Keywords


Febrile Neutropenia, Chemotherapy, Cancer, Myelosuppressive, MASCC FN risk index score scale.

Full Text:

PDF

References


https://www.cancer.gov/about-cancer/understanding/statistics.

https://www.who.int/news-room/fact-sheets/detail/cancer.

http://globalrt.org/about-cancer/

Lyman GH, Rolston KV. How we treat febrile neutropenia in patients receiving cancer chemotherapy. J Oncol Pract. 2010;6(3):149-152.

Aapro MS, Cameron DA, et al. Working Party EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006;42:2433–2453.

Freifeld AG, Bow EJ, et al. Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-e93.

Neutropenia. American Society of Clinical Oncology website. www.cancer.net/navigating-cancer-care/side-effects/neutropenia. Published October 2016. Accessed August 2017.

Wingard JR. Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults. UpToDate website. www.uptodate.com/contents/prophylaxis-of-infection-during-chemotherapy-induced-neutropenia-in-high-risk-adults. Updated September 13, 2016. Accessed August 2017.

Bodey GP, Buckley M, et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328–340.

Clark OA, Lyman GH, Castro AA, Clark LG, Djulbegovic B. Colony stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23(18):4198-4214.

Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis. 2004;39 Suppl 1:S32-7.

Nesher L, Rolston KV. The current spectrum of infection in cancer patients with chemotherapy related neutropenia. Infection. 2014;42(1):5-13.

Eun Ha Y, Song JH, et al. Clinical factors predicting bacteremia in low-risk febrile neutropenia after anti-cancer chemotherapy. Support Care Cancer 2011;19:1761–1767.

Feld R, Paesmans M, et al. Immunocompromised Host Society; Multinational Association for Supportive Care in Cancer. Methodology for clinical trials involving patients with cancer who have febrile neutropenia: updated guidelines of the Immunocompromised Host Society/Multinational Association for Supportive Care in Cancer, with emphasis on outpatient studies. Clin Infect Dis. 2002;15;35(12):1463-8.

Freifeld A, Marchigiani D, Walsh T et al. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 1999;341:305–3011.

Kern WV, Cometta A, De Bock R et al. Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 1999;314:312–318.

Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2002;Aug;18(16):3038-51.

U.V. Mateti, A.M. Sebastian, et al. Assessment of Chemotherapy Induced Febrile Neutropenia in Cancer Patients - A Prospective Observational Study in South India. Annals of Oncology (2017) 28 (suppl_10): x155-x165.

Aagaard T, Roen A, Reekie J, et al. Development and Validation of a Risk Score for Febrile Neutropenia After Chemotherapy in Patients With Cancer: The FENCE Score. JNCI Cancer Spectr. 2018 Nov 29;2(4):pky053.

Hashiguchi Y, Kasai M, Fukuda T, et al. Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy. Anticancer Drugs. 2015 Nov;26(10):1054-60.

Ishikawa T, Sakamaki K, Narui K, et al. Prospective cohort study of febrile neutropenia in breast cancer patients with neoadjuvant and adjuvant chemotherapy: CSPOR-BC FN study. Jpn J Clin Oncol. 2016 Jul;46(7):692-5.


Refbacks

  • There are currently no refbacks.